.jpg?format=webp&width=780)
The study aims to estimate the cost-effectiveness of using SGLT2 inhibitors in the management of type 2 diabetes mellitus (T2DM) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic heart failure or high risk of CVD. The study used the Cardiff type 2 diabetes model and considered both cardio- and reno-protective effects of SGLT2 inhibitors. Results showed that SGLT2 inhibitor introduction was cost-effective and became cost-saving between 2 and 16 years post-initiation, resulting in incremental gains in quality-adjusted life years and a potential to lower healthcare costs while improving health outcomes. The study incorporated the totality of proven health benefits, including evidence from cardiovascular outcomes trials but not from chronic kidney disease trials.
Like
Save
Share